Validation of MRI Surrogates
Traditionally, the clinical endpoints used to monitor clinical trials in multiple sclerosis (MS) are the occurrence of relapses (usually expressed as a rate over time), and the degree of disability, most commonly evaluated using the Expanded Disability Status Scale (EDSS) .
KeywordsMultiple Sclerosis Expand Disability Status Scale Secondary Progressive Multiple Sclerosis Baseline Expand Disability Status Scale Secondary Progressive Multiple Sclerosis Patient
Unable to display preview. Download preview PDF.
- 6.Comi G, Filippi M, Wolinsky JS and the European/Canadian Glatiramer Acetate Study Group (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49:290–297PubMedCrossRefGoogle Scholar